Oral direct thrombin inhibition: a double-edged sword?

Area of Science:

• Cardiology
• Pharmacology
• Thrombosis Research

Background:

• New oral anticoagulants (NOACs) demonstrate non-inferiority to vitamin K antagonists for thromboembolic event prevention in non-valvular atrial fibrillation and venous thromboembolism.
• Certain NOACs, specifically direct thrombin inhibitors, have been linked to an increased risk of myocardial infarction.

Purpose of the Study:

• To review the pleiotropic physiological effects of thrombin.
• To explore the potential association between thrombin's physiological effects and the observed higher incidence of myocardial infarction with oral direct thrombin inhibitors.
• To evaluate the implications for patient populations, particularly those with coronary artery disease.

Main Methods:

• Literature review and analysis of existing studies on new oral anticoagulants.
• Examination of the physiological roles of thrombin beyond coagulation.
• Correlation analysis between direct thrombin inhibitor therapy and myocardial infarction incidence.

Main Results:

• Direct thrombin inhibitors are associated with a greater risk of myocardial infarction compared to other anticoagulants.
• Thrombin possesses multiple physiological functions that could influence cardiovascular risk.
• The precise mechanisms linking direct thrombin inhibition to myocardial infarction require further elucidation.

Conclusions:

• Further research is essential to clarify the cardiovascular safety profile of oral direct thrombin inhibitors.
• High-risk patients and those with established coronary artery disease should be carefully monitored or considered for alternative anticoagulants.
• Current evidence suggests prudence in prescribing direct thrombin inhibitors for patients with existing coronary artery disease.